TABLE 1.

Characteristics of 6306 Patients of Age 0–65 at HCT^a and Known Race who Survived at Least 100 Days after HCT, by Inclusion of TBI in Conditioning Regimen

		No TBI (N = 2436)		TBI (N = 3870)
		No.	%	No.	%
Sex
	Female	1227	50.4%	1622	41.9%
	Male	1209	49.6%	2248	58.1%
Race
	White	2154	88.4%	3512	90.8%
	Non-white	282	11.6%	358	9.2%
Age at HCT (years)
	0–17	376	15.4%	1006	26.0%
	18–44	1023	42.0%	2194	56.7%
	45–65	1037	42.6%	670	17.3%
Year of HCT
	1969–1975	34	1.4%	68	1.8%
	1976–1980	88	3.6%	308	8.0%
	1981–1985	83	3.4%	630	16.3%
	1986–1990	226	9.3%	887	22.9%
	1991–1995	532	21.8%	916	23.7%
	1996–2000	645	26.5%	693	17.9%
	2001–2005	828	34.0%	368	9.5%
Cell source
	Autologous	924	37.9%	502	13.0%
	Matched related donor	1070	43.9%	1843	47.6%
	Mismatched related donor	75	3.1%	477	12.3%
	Matched unrelated donor	322	13.2%	1029	26.6%
	Unknown	45	1.8%	19	0.5%
AGVHD
	Grade 0–1	1454	59.7%	1274	32.9%
	Grade 2–4	982	40.3%	2596	67.1%
Clinical extensive CGVHD
	No	1660	68.1%	2221	57.4%
	Yes	776	31.9%	1649	42.6%
Prior exposure to radiation therapy
	Probably not exposed	1041	42.7%	2290	59.2%
	Possibly not exposed	488	20.0%	118	3.1%
	Possibly exposed	347	14.2%	496	12.8%
	Probably exposed	560	23.0%	966	25.0%
		Mean	Min–Max	Mean	Min–Max
Age at HCT (years)		38.1	0.3–65	28.8	0.5–65
Duration of follow-up (years)		5.8	0.3–33.1	6.6	0.3–36.2

^aAbbreviations: AGVHD, acute graft-versus-host disease, CGVHD, chronic graft-versus-host disease; HCT, hematopoietic cell transplantation; TBI, transplant population irradiated as part of conditioning regimen.